
J&J’s Lung Cancer Combo Bests AstraZeneca’s Tagrisso, Reducing Risk of Death 25%
A combo regimen of Johnson & Johnson’s Rybrevant and Lazcluze significantly prolonged overall survival in non-small cell lung cancer patients, beating AstraZeneca’s Tagrisso in a late-stage trial. “We view today’s update as an incremental positive for …